We examined the association of opioid misuse from ages 18 to 20 with four domains at age 21–22: risk behaviors and consequences; health; social functioning; and emerging adult roles.
This is the first study to evaluate the feasibility of using a text messaging-based intervention (TMI) for behavior change with 18–25 year olds experiencing homelessness, and the first to test a TMI to provide ongoing support for smoking cessation.
Wilkins & Rychert highlight challenges to achieving the Cannabis Legalization and Control Bill's objectives of reducing cannabis use and harms.
We study the effect of state recreational marijuana laws on workers' compensation benefit receipt among adults 40–62 years old.
In this paper, we find that over a longer time horizon, OxyContin reformulation stimulated illicit drug markets to grow and evolve.
This paper examines how the recent transition of the opioid crisis from prescription opioids to more prevalent misuse of illicit opioids, such as heroin and fentanyl, altered labor supply behavior and disability insurance claiming rates.
Here we explore the important case of using General Population Surveys to estimate frequent heroin use.
We compared relative prevalences across 6 racial/ethnic groups for prescription opioid misuse analyses and 4 racial/ethnic groups for heroin analyses.
This cross-sectional study examined how transaction sales limits on recreational cannabis translate to tetrahydrocannabinol doses among U.S. states allowing commercial cannabis sales as of January 1, 2020.
This study identifies distinct patterns (classes) of substance use among 30- to 80-year olds, identifies demographic subgroups with the highest probability of class memberships, and compares classes on key indicators of functioning.
The opioid epidemic has claimed the lives of more than 450,000 Americans since 1999. Amid claims that the pharmaceutical industry used misleading tactics to downplay the known harms of prescription opioids, more than 2,000 plaintiffs have joined the largest civil trial in U.S. history: National Prescription Opiate Litigation (MDL 2804). In this symposium, experts discuss the opioid litigation and its effects on the future of mass litigation.
While many illegally manufactured potent synthetic opioids (IMPSO) are produced in Asia, there is little evidence they have entered markets there. We consider the susceptibility to IMPSO's encroachment in markets in the Asia-Pacific region.
Rates of cigarette smoking and use of other tobacco products (e.g., e-cigarettes or vapes) among youth experiencing homelessness are extremely high. This manual contains an easy-to-use guide for service providers to deliver brief and inexpensive assistance to youth experiencing homelessness who want to stop using tobacco products.
Our findings lend empirical support for implementation theories in that multiple factors appear to be associated with long-term delivery of an evidence-based treatment.
We sought to examine, among individuals treated in publicly funded community mental health clinics, perceived need for and attitudes toward medications for alcohol use disorder.
Commentary on an article by Truong, Patil, and Rich, on the benefits and dangers of naloxone prescriptions.
Commentary on an article by Azcarate et al., assessing U.S. adults' motivations for and perceived physician attitudes towards medical cannabis use.
This paper is the first to examine cannabis market data from Washington alongside that from Oregon, two states that are similar in regard to legalizing retail sales of cannabis but differ in terms of their regulatory frameworks.
In this Perspective, we describe three strategies hospitals can use to multiply the reach of their opioid settlement funding by addressing root causes of opioid use through primary prevention.
We analyze substance use, AI/AN cultural identity and involvement, physical health and cognitive functioning, and mental health symptoms among 63 AI/AN adults seeking substance use treatment within an urban area in California.
In this paper, we provide an overview of methodological challenges facing opioid policy researchers when conducting opioid policy evaluation studies using observational data, as well as some potential solutions to those challenges.
In the context of the pandemic, buprenorphine prescribers quickly transitioned to providing telemedicine visits in high volume; nonetheless, there are still many unknowns, including the quality and safety of widespread use of telemedicine for OUD treatment.
The goal of this exploratory project is to help fill gaps in the literature by empirically measuring levels of explicit provider-based stigma toward persons who use opioids.
A national longitudinal survey of 1,540 adults ages 30-80 in 2019 and 2020 shows that people drank more frequently, and for women in particular, more heavily and with more negative consequences, during the initial stages of the COVID-19 pandemic.
We conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine.
